Mazyar Shadman, MD, MPH, is the Innovators Network Endowed Chair and an associate professor, in theClinical Research Division at Fred Hutchinson Cancer. He is also an associate professor in the Medical Oncology Division at University of Washington School of Medicine.

Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Dr. Mazyar Shadman presents a network meta-analysis evaluating Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL, showing that zanubrutinib demonstrated the greatest efficacy in reducing progression and death compared to other BTK inhibitors and treatments.

Comparative Efficacy of Bruton Tyrosine Kinase Inhibitors in High-Risk Relapsed/Refractory CLL: A Network Meta-Analysis